Article
Agriculture, Dairy & Animal Science
Jinhee H. Hwang, Michael E. Spurlock, John C. Kube, Xiang Z. Li, Stephen B. Smith
Summary: The study revealed that lubabegron fumarate is highly selective for the beta(3)-adrenergic receptor subtype and has minimal agonistic activity at the beta(2)-adrenergic receptor. Differences in mRNA expression levels of beta(1)-, beta(2)-, and beta(3)-AR were observed between subcutaneous and intramuscular adipose tissues. The response to beta-adrenergic ligands, especially agonists for the beta(1)- and beta(3)-receptor subtypes, was found to be lower in intramuscular adipose tissue compared to subcutaneous adipose tissue.
JOURNAL OF ANIMAL SCIENCE
(2021)
Article
Chemistry, Medicinal
Gabriele Carullo, Sarah Mazzotta, Margarita Vega-Holm, Fernando Iglesias-Guerra, Jose Manuel Vega-Perez, Francesca Aiello, Antonella Brizzi
Summary: The GPCRs activated by FFAs have become a new and exciting drug target, with a focus on GPR120 in diseases such as cancer and inflammatory conditions. Research on GPR120 agonists, particularly in the context of Type 2 diabetes mellitus, has paved the way for potential antidiabetic drug discovery.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Cell Biology
Marine Tournissac, Manon Leclerc, Josue Valentin-Escalera, Milene Vandal, Cristina R. Bosoi, Emmanuel Planel, Frederic Calon
Summary: Alzheimer's disease (AD) is a complex age-related neurodegenerative disease associated with central and peripheral metabolic anomalies, such as impaired glucose utilization and insulin resistance. Correcting thermoregulatory impairments could slow the progression and delay the onset of AD.
AGEING RESEARCH REVIEWS
(2021)
Article
Peripheral Vascular Disease
Raj Desai, Haesuk Park, Joshua D. Brown, Rajesh Mohandas, Carl J. Pepine, Steven M. Smith
Summary: In patients with resistant hypertension, using aldosterone antagonists as a fourth-line antihypertensive agent does not significantly reduce the risk of major adverse cardiovascular events, but it does significantly increase the risk of hyperkalemia, gynecomastia, and kidney function deterioration.
Article
Chemistry, Medicinal
Jianfang Chen, Jiangting Liu, Yuan Yuan, Xin Chen, Fuhui Zhang, Xuemei Pu
Summary: This study explores the molecular mechanisms of biased activation induced by structural differences between different agonists. It reveals that G-protein-biased agonists and fi-arrestin-biased agonists achieve biased signaling through different conformational changes. In addition, the study also identifies specific conformations of ICL3 under specific agonists and the roles of key residues. These findings contribute to a better understanding of biased activation mechanisms and provide guidance for the design of biased drugs.
JOURNAL OF CHEMICAL INFORMATION AND MODELING
(2022)
Article
Endocrinology & Metabolism
Kim Z. Rokamp, Flemming Dela, Niels H. Secher, Lars Gronlykke, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard
Summary: This study investigates the impact of the ADRB2 gene polymorphism Gly16Arg on the metabolic response to epinephrine before and after repetitive hypoglycemia. The results showed that the insulin, glycerol, and free fatty acid responses to epinephrine were decreased in participants with the Arg16 genotype compared with those with the Gly16 genotype before hypoglycemia, but there was no difference in glucose response. However, there were no differences in response to epinephrine between genotype groups after repetitive hypoglycemia.
Article
Medicine, Research & Experimental
Kirti Singh, Razan L. Teyani, Nader H. Moniri
Summary: Asthma and other airway obstructive disorders are characterized by heightened inflammation and oxidative environment, while beta 2-adrenergic receptor (beta 2AR) agonists are still the first-line treatment option for asthma, chronic use may lead to increased tolerance to bronchorelaxant effects possibly due to hyperoxidation of beta 2AR to S-sulfinic acids.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Neurosciences
Danique R. Hutten, Jens H. J. Bos, Stijn de Vos, Eelko Hak
Summary: This retrospective inception cohort study found that exposure to non-selective beta AR antagonists may increase the risk of developing Alzheimer's disease in older adults, while exposure to selective beta 2AR agonists may decrease the risk.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Respiratory System
Teresa To, Jingqin Zhu, Emilie Terebessy, Kimball Zhang, Andrea S. Gershon, Christopher Licskai
Summary: Recent studies have shown that overuse of short-acting beta(2)-agonists (SABA) is common among older asthma patients, and is associated with adverse outcomes.
Review
Veterinary Sciences
Alison P. Pfau, Elizabeth A. Shepherd, M. Gabbi Martin, Sophia Ascolese, Katie M. Mason, Amanda M. Egert-McLean, Brynn H. Voy, Phillip R. Myer
Summary: The beef industry is facing the challenge of increasing protein supply to a growing global population. Improving nutrient use efficiency and addressing the rumen microbial community are important for enhancing the sustainability of the industry. Beta-adrenergic agonists and dietary protein play critical roles in beef cattle production, with beta-agonists enhancing growth and feed efficiency, and dietary protein providing necessary nutrients. By optimizing rumen fermentation, diet, and growth-promoting technologies, the industry can improve energy capture and performance. Research and development in this field can lead to innovative solutions that benefit both producers and the environment.
VETERINARY SCIENCES
(2023)
Review
Cardiac & Cardiovascular Systems
Wai Hong Wilson Tang, Sathyamangla V. Naga Prasad
Summary: The antibody response to self-antigens plays a crucial role in cardiovascular disease. Autoantibodies that modulate receptor signaling have diverse effects, but their exact role and mechanisms are still not well-understood.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2022)
Article
Critical Care Medicine
Darryl Abrams, Cara Agerstrand, Jeremy R. Beitler, Christian Karagiannidis, Purnema Madahar, Natalie H. Yip, Antonio Pesenti, Arthur S. Slutsky, Laurent Brochard, Daniel Brodie
Summary: Ultra-lung-protective ventilation is a strategy that aims to achieve lower airway pressures and tidal volumes. Some patients may benefit from this strategy, but its application is limited by respiratory acidosis and associated hematological complications. Only in very severe cases of acute respiratory distress syndrome, using extracorporeal membrane oxygenation to accomplish ultra-lung-protective ventilation may have a favorable risk-to-benefit profile.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Stefano Genovese, Irene Caruso, Francesco Giorgino
Summary: This study compared the effectiveness and safety of GLP-1 RA and SGLT-2i in a large cohort of patients with type 2 diabetes. The results showed that GLP-1 RA was equally safe but more effective than SGLT-2i in reducing the risk of major adverse cardiovascular events and non-fatal myocardial infarction. The incidence of serious adverse events was low in both treatment groups.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Iain L. O. Buxton, Hazik Asif, Scott D. D. Barnett
Summary: Preterm labor leading to preterm birth is currently not preventable. Beta 2 agonists and nitric oxide, which are effective in relaxing smooth muscles, have been ineffective in preventing preterm birth. However, recent studies suggest that the repurposing of approved medication, such as mirabegron, may advance the prevention of preterm birth.
Review
Pharmacology & Pharmacy
Jean-Luc Balligand, Lauriane Y. M. Michel
Summary: This article discusses the benefits and safety of beta 3-adrenoreceptor agonists on cardiovascular outcomes. Based on limited evidence from small clinical trials, mirabegron, a beta 3-agonist, appears to be safe in patients at high cardiovascular risk but only produces benefits on selected cardiovascular outcomes at higher doses. Testing more potent beta 3-adrenoreceptor agonists, such as vibegron, is necessary.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2023)